Novo Nordisk A-S

Discover how Novo Nordisk’s partnership with Abbott India and FDA approval of Sogroya broaden its diabetes, obesity and pediatric therapy reach—boosting global market growth.

Novo Nordisk’s latest moves—Vivtex licensing for oral diabetes therapy, expanded Sogroya approval, and the Indian Extensior launch—reshape its growth strategy, offering new revenue streams amid rising competition and regulatory shifts.

New partnership with Vivtex could bring oral biologics for obesity and type 2 diabetes, boosting Novo Nordisk’s pipeline while maintaining strong fundamentals and dividend policy.

New data show Novo Nordisk’s NVS‑Obes‑1 failed to beat semaglutide in weight‑loss, causing a sharp share drop, but the company remains focused on diabetes and next‑gen GLP‑1 therapies.

Novo Nordisk’s oral semaglutide 25mg, a once-daily tablet for weight loss, achieved significant weight loss and improved cardiovascular risk factors in a 52-week trial, with a safety profile comparable to its injectable counterpart.

Novo Nordisk’s stock price has surged after the release of positive data on its weight-loss drug Wegovy, which has demonstrated stronger heart-protective benefits compared to rival therapies.

Novo Nordisk’s stock price has plummeted 4.5% due to concerns that Eli Lilly’s successful weight loss pill, Orforglipron, will erode the company’s market share.

Novo Nordisk A-S’s stock price has rebounded due to its successful GLP-1 drug market and recent court victories, despite concerns about growth and the company’s decision to cut staff bonuses.

Novo Nordisk A/S’s stock price has increased following the approval of its weight loss medication, Wegovy, which is expected to give the company a competitive edge in the market.

Novo Nordisk’s stock price has plummeted by 30% after the company revised its annual forecast, with institutional investors selling shares and small investors buying in anticipation of a potential rebound.